Aisa Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aisa Pharma is a clinical-stage biotech company developing AISA-021, a novel 4th generation dual-channel calcium blocker, for the treatment of Raynaud's phenomenon secondary to systemic sclerosis, a severe autoimmune disease with high unmet need. The company has completed Part 1 of its Phase 2 RECONNOITER-1 study in Australia and is nearing completion of Part 2, with encouraging preliminary clinical data suggesting effects on both Raynaud's and underlying disease symptoms. Founded in 2018 by CEO Andrew Sternlicht, M.D., the company leverages a team with extensive drug development experience and a strategy of repurposing known drug classes to improve efficacy and tolerability for underserved patient populations.

Rare DiseasesAutoimmune DiseasesVascular Diseases

Technology Platform

Repurposing and optimization of calcium channel blockers to create novel, fourth-generation dual-channel (including N-type) blockers with improved efficacy and tolerability profiles.

Opportunities

Aisa-021 addresses a severe unmet need in a rare disease population (scleroderma patients with Raynaud's) with no specifically approved therapy, allowing for potential orphan drug designation, premium pricing, and expedited regulatory pathways.

Positive data could also enable expansion into other neurovascular or pain indications, broadening the asset's value.

Risk Factors

The company faces significant clinical risk as its entire value depends on the success of a single, mid-stage asset (AISA-021) in an ongoing Phase 2 trial.

As a private, pre-revenue firm, it also carries substantial financial risk, requiring successful future capital raises to fund pivotal studies and operations.

Competitive Landscape

The competitive landscape consists of generic calcium channel blockers (e.g., nifedipine) and other vasodilators used off-label, which are often limited by side effects. There are no drugs specifically approved for Raynaud's in scleroderma, but Aisa-021 may face future competition from other novel vasodilators or disease-modifying therapies in development for systemic sclerosis.

More companies in Small Molecule Drugs →More companies in United States →